Spleen News and Research

RSS

Hebrew University of Jerusalem receives $5 million grant from Bill & Melinda Gates Foundation

The Hebrew University of Jerusalem Kuvin Center for the Study of Infectious and Tropical Diseases has received a $5 million grant from the Bill & Melinda Gates Foundation for research into visceral leishmaniasis in Ethiopia.

17 Dec 2009

Hebrew University of Jerusalem granted $5M for research into visceral leishmaniasis in Ethiopia

17 Dec 2009

Retrospective study demonstrates new survival data for patients with myelofibrosis

A recent study, published in the December issue of Mayo Clinic Proceedings, demonstrates new survival data for the blood disorder myelofibrosis. This retrospective study is the largest ever conducted in young patients with primary myelofibrosis.

15 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Expert advice for organ transplant surgeons on clinical issues posed by swine flu pandemic

Surgeons and other healthcare professionals specialising in solid organ transplants have been issued with expert advice to guide them through the complex clinical issues posed by the global H1N1 (swine flu) pandemic.

4 Dec 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Experiments explain factors behind common malarial symptoms

When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells. Inside the blood cells, the parasites replicate and also begin to expose adhesive proteins on the cell surface that change the physical nature of the cells in the bloodstream.

23 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

Scientists identify molecular disparity between iPS cells and embryonic stem cells

The same genes that are chemically altered during normal cell differentiation, as well as when normal cells become cancer cells, are also changed in stem cells that scientists derive from adult cells, according to new research from Johns Hopkins and Harvard.

5 Nov 2009

Scientists identify compounds that hold promise for treating parasitic infection

Using an unconventional approach that they designed, University of Pittsburgh drug discoverers and their collaborators at Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection that many consider one of the world's most overlooked diseases.

4 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

CryoLife granted FDA approval for BioFoam human clinical trial

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology.

27 Oct 2009

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Doctoral candidate sheds new light on the biology of Leishmania parasites

Professor Albert Descoteaux's team at Centre INRS - Institut Armand-Frappier has gained a better understanding of how the Leishmania donovani parasite manages to outsmart the human immune system and proliferate with impunity, causing visceral leishmaniasis, a chronic infection that is potentially fatal if left untreated.

24 Oct 2009

Positive results from Protalix BioTherapeutics Phase III UPLYSO clinical trial

Protalix BioTherapeutics, Inc., announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO (taliglucerase alfa, previously referred to as prGCD) in treatment naive patients diagnosed with Gaucher disease.

15 Oct 2009

Specific immune system cells linked to susceptibility of younger people to variant CJD

Specific cells within the immune system could help explain why younger people are more susceptible to variant CJD, scientists believe.

15 Oct 2009

NanoBio to receive a $4.1M subcontract for developing nanoemulsion-based mucosal vaccine adjuvants

NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan.

14 Oct 2009

Destructive immune cells gain access to insulin-producing cells and help cause diabetes

St. Jude Children's Research Hospital investigators have discovered how destructive immune cells gain access to insulin-producing cells and help cause diabetes.

9 Oct 2009